Aspirin Versus Aspirin + ClopidogRel Following Transcatheter Aortic Valve Implantation: the ARTE Trial

PHASE4CompletedINTERVENTIONAL
Enrollment

178

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

March 31, 2015

Study Completion Date

March 31, 2016

Conditions
Aortic Valve DiseaseMyocardial InfarctionStroke
Interventions
DRUG

Aspirin (80 mg/d) + clopidogrel (75 mg/d)

Aspirin (80 mg/d) + clopidogrel (75 mg/d) Aspirin therapy will start at least 24 hrs before the TAVI procedure and continued for at least 6 months. Clopidogrel therapy will start within 24 hrs before the TAVI procedure in cases where a transfemoral approach is used and within 24 hrs after the TAVI procedure in cases where a transapical approach is used. The initial dose of clopidogrel will be of 300 mg followed by 75 mg/die. The duration of clopidogrel treatment will be of 3 months. Patients will be followed either by phone contact or clinical visits at 1- and 12-month follow-up.

DRUG

Aspirin

Aspirin (80 mg/d) Aspirin therapy will start at least 24 hrs before the TAVI procedure and continued for at least 6 months.

Trial Locations (2)

V6Z 1Y6

St-Paul's Hospital, Vancouver

G1V 4G5

IUCPQ, Québec

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Edwards Lifesciences

INDUSTRY

lead

Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec

OTHER